Trump touts Medicaid drug savings
President Trump said Friday that all 50 states, Washington, D.C., and Puerto Rico have applied to join a program designed to secure lower drug prices for Medicaid, and he predicted the initiative could help his party in the midterm elections. He made the remarks to reporters in the Oval Office and noted that 40 states and Puerto Rico have already signed agreements related to the effort.
Why It Matters
If fully implemented, broad participation by states in a Medicaid drug pricing arrangement could affect how publicly funded prescription drug programs purchase medications and negotiate prices. The president tied the policy development directly to political messaging ahead of the midterm elections.
Key Facts
- Who applied: All 50 states, Washington, D.C., and Puerto Rico
- Purpose: Arrangement intended to give lower drug prices to Medicaid programs
- Signed agreements so far: 40 states and Puerto Rico
- Where statement made: Oval Office
- President's comment: “This one thing alone should win us the midterms,” Trump told reporters
President Trump announced Friday that all 50 U.S. states, the District of Columbia and Puerto Rico have applied to participate in an arrangement aimed at lowering drug costs for Medicaid programs. He spoke to reporters in the Oval Office and framed the initiative as both a policy achievement and a potential political advantage ahead of the midterm elections.
Trump said that 40 states plus Puerto Rico have already signed agreements tied to the effort. He emphasized the measure's potential electoral impact, telling reporters, “This one thing alone should win us the midterms.”
The administration presented the arrangement as intended to deliver reduced prescription drug prices for Medicaid, though details about the program’s mechanics or next steps were not included in the remarks quoted. The president’s comments combined policy description with a direct appeal to voters, linking a health-care initiative to political outcomes.
Beyond the president’s statements, the announcement indicates significant state-level engagement with the proposed drug-pricing arrangement, with all jurisdictions applying and a substantial portion of them having formalized agreements to participate.
Keep Reading
Court reinstates $7B ‘Solar for All’ program axed by Trump
Trump says son paid back Russian oligarch for wedding gift
Trump says he still backs Salazar after video criticizing him on immigration
